Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.71 HKD | -1.38% | -1.89% | -15.16% |
May. 23 | Simcere Pharmaceutical Group's Hypnotic Drugs Gets the Nod from Hong Kong Authorities | MT |
Apr. 25 | Simcere Pharmaceutical’ Profit Down 23% in 2023 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-15.16% | 1.86B | - | ||
+16.31% | 42.32B | B- | ||
+15.75% | 21.29B | B+ | ||
+19.33% | 15.29B | - | ||
+18.71% | 14.36B | B+ | ||
+52.78% | 12.81B | B | ||
-0.05% | 6.79B | - | - | |
-12.58% | 6.58B | B+ | ||
-8.87% | 5.73B | - | - | |
+14.28% | 5.51B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 2096 Stock
- Ratings Simcere Pharmaceutical Group Limited